3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Vitamin D Deficiency
2
Prostatic Neoplasms
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Osteoporosis Secondary
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Biphenotypic, Acute
1
Colonic Neoplasms
1
Interventions
Rituximab
39
Cyclophosphamide
35
Magnetic Resonance Spectroscopy
22
Specimen Handling
20
Doxorubicin
18
polatuzumab vedotin
17
Prednisone
17
Lenalidomide
15
Biopsy
15
fludarabine
13
Oxaliplatin
13
Gemcitabine
13
zanubrutinib
11
Vincristine
11
Immunotherapy, Adoptive
10
Etoposide
10
glofitamab
9
axicabtagene ciloleucel
7
Prednisolone
7
obinutuzumab
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Leukapheresis
6
Injections
6
Ifosfamide
6
Bendamustine Hydrochloride
6
loncastuximab tesirine
5
ibrutinib
5
acalabrutinib
5
Carboplatin
5
CT-P10
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma, Large B-Cell, Diffuse
×
Cholecalciferol
×
Clear all
NCT04442412
2022-08-26
FIL_PREVID
Fondazione Italiana Linfomi - ETS
Phase 3
Recruiting
430 enrolled